Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Curis Inc (NQ: CRIS )

10.52 USD +0.15 (+1.45%)
Official Closing Price Updated: 6:11 PM EDT, Apr 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,090,428
Open 10.37
Bid (Size) 10.40 (2)
Ask (Size) 10.80 (2)
Prev. Close 10.37
Today's Range 10.11 - 10.96
52wk Range 0.6850 - 13.44
Shares Outstanding 91,507,498
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration... 
From PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent... 
From PR Newswire

Performance

YTD
+16.50%
+16.50%
1 Month
-17.62%
-17.62%
3 Month
-8.92%
-8.92%
6 Month
+799.15%
+799.15%
1 Year
+1381.48%
+1381.48%

More News

Read More
Curis to Present at 20th Annual Needham Virtual Healthcare Conference
From PR Newswire
Curis Reports Fourth Quarter and Year-End 2020 Financial Results
From PR Newswire
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting
From PR Newswire
Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021
From PR Newswire
Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference
From PR Newswire
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
From PR Newswire
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
From PR Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Tags STRM Market News VYNT
From Benzinga
CRIS Crosses Above Average Analyst Target
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.